Truist Financial Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report). The company’s shares opened today at $8.63.

Lee covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Wave Life Sciences, and Catalyst Pharma. According to TipRanks, Lee has an average return of 23.7% and a 48.32% success rate on recommended stocks.

Voyager Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.50, representing a 102.78% upside. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $14.00 price target.

Based on Voyager Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $90.06 million and a net profit of $56.4 million. In comparison, last year the company had a GAAP net loss of $23.63 million

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics (VYGR) Company Description:

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.